[Effect of various forms of human leukocyte interferon on the natural killer activity of human lymphocytes]. 1982

I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova

The effect of the preparations of human leucocytic interferon (HLI) of various purity levels and of various concentrations was studied with respect to the natural killer activity of human leucocytes. It was shown that the process of purification and concentration of the preparation of HLI with the Kantel method entailed a disproportionally high loss of the activity stimulating the natural killer cells as compared to the antiviral activity.

UI MeSH Term Description Entries
D007370 Interferon Type I Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). Interferons Type I,Type I Interferon,Type I Interferons,Interferon, Type I,Interferons, Type I
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D003601 Cytotoxicity Tests, Immunologic The demonstration of the cytotoxic effect on a target cell of a lymphocyte, a mediator released by a sensitized lymphocyte, an antibody, or complement. AHG-CDC Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Tests,Microcytotoxicity Tests,Anti Human Globulin Complement Dependent Cytotoxicity Tests,Anti-Human Globulin Complement-Dependent Cytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Test,Antiglobulin-Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunologic,Cytotoxicity Tests, Anti-Human Globulin Complement-Dependent,Cytotoxicity Tests, Immunological,Immunologic Cytotoxicity Test,Immunologic Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin-Augmented,Lymphocytotoxicity Tests, Antiglobulin-Augmented,Microcytotoxicity Test,AHG CDC Tests,AHG-CDC Test,Anti Human Globulin Complement Dependent Cytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Test,Antiglobulin Augmented Lymphocytotoxicity Tests,Cytotoxicity Test, Immunological,Cytotoxicity Tests, Anti Human Globulin Complement Dependent,Immunological Cytotoxicity Test,Immunological Cytotoxicity Tests,Lymphocytotoxicity Test, Antiglobulin Augmented,Lymphocytotoxicity Tests, Antiglobulin Augmented
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D013268 Stimulation, Chemical The increase in a measurable parameter of a PHYSIOLOGICAL PROCESS, including cellular, microbial, and plant; immunological, cardiovascular, respiratory, reproductive, urinary, digestive, neural, musculoskeletal, ocular, and skin physiological processes; or METABOLIC PROCESS, including enzymatic and other pharmacological processes, by a drug or other chemical. Chemical Stimulation,Chemical Stimulations,Stimulations, Chemical

Related Publications

I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
December 1983, Gan,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
February 1985, Gan to kagaku ryoho. Cancer & chemotherapy,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
June 1982, Orvosi hetilap,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
January 1986, Blood,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
March 1993, Brain, behavior, and immunity,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
September 1991, Hepatology (Baltimore, Md.),
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
January 1994, Mediators of inflammation,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
October 1982, Molecular immunology,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
December 1994, Biulleten' eksperimental'noi biologii i meditsiny,
I V Timofeev, and V P Kuznetsov, and E G Slavina, and T P Timofeeva, and T G Orlova
January 1982, Immunology letters,
Copied contents to your clipboard!